Are the MDS‐UPDRS–Based Composite Scores Clinically Applicable?

Abstract

Our findings support the application of various MDS-UPDRS-based composite scores. © 2018 International Parkinson and Movement Disorder Society.

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer

“…This is in line with findings examining the old UPDRS scale [28]. Although several studies have suggested that composite scores are able to detect clinically relevant differences over time [26,27,29], the authors of the new scale clearly recommended against the use of I-III composite scores as their unequal factorial loading reduces sensitivity to change [17].…”

“…However, changes in the MDS-UPDRS total score (within the first five years of disease) are largely driven by changes in the MDS-UPDRS Part III score; as part I and II score changes are not as pronounced over time [26] their addition into a total score may reduce sensitivity to change [27]. This is in line with findings examining the old UPDRS scale [28].…”

“…Whilst some data indicate that overall disease progression up to at least five years from diagnosis is linear [26,31,32], it is generally accepted that the rate of motor symptom decline decelerates beyond five years [28,[32][33][34]. Progression studies using the revised scale are only just emerging [26,27,35]; to date these studies do not report data of patients beyond five years of disease, representing an important knowledge gap.…”

Acceptability and practicability of self-management for patients with Parkinson’s disease based on smartphone applications in China

“…The questionnaire ( Supplementary file ) consisted of Part I, Part II, Part III, and Part IV. Part I pertained to patient characteristics, including demographic data (age, gender, educational level, occupation) and the main clinical features of PD (PD disease course, number of anti-PD drugs, Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [ 20 ], and Hoehn & Yahr Stage (H & Y) [ 21 ]).…”

Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale

“…Although Mestre et al [11] demonstrated that a 2.32-point change on the clinician-rated UDysRS Part 3 is the threshold for clinical relevance, the MCID estimates for the historic parts of the UDysRS have not yet been calculated. Although our team evaluated the MCID thresholds for Parts I [12], II [12], III [13], and the total score [14] of the MDS-UPDRS, the size of the minimally required change on the MDS-UPDRS MC is still unknown.…”